3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Interventions
Tacrolimus
2
Specimen Handling
2
Lymphatic Irradiation
2
Biopsy
2
venetoclax
1
selinexor
1
olutasidenib
1
fludarabine phosphate
1
fludarabine
1
decitabine and cedazuridine drug combination
1
Thiotepa
1
Sirolimus
1
Receptors, Antigen, T-Cell
1
Quality of Life
1
Peripheral Blood Stem Cell Transplantation
1
Melphalan
1
Maintenance
1
Levofloxacin
1
Idarubicin
1
Fibroblast Growth Factor 7
1
Electrocardiography
1
Cytarabine
1
Clinical Laboratory Techniques
1
Busulfan
1
Bone Marrow Examination
1
Blood Specimen Collection
1
Azacitidine
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Myelodysplastic Syndromes
×
Receptors, Antigen, T-Cell
×
Clear all
NCT06463327
2024-06-17
ACHIEVE2
TC Biopharm
Phase 1
Not yet recruiting
69 enrolled